Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

NCT04747496 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-01-09

No results posted yet for this study

Summary

The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.

Conditions

  • Non-valvular Atrial Fibrillation

Interventions

DRUG

Edoxaban

This is a non-interventional, observational study.

Sponsors & Collaborators

  • Daiichi Sankyo Co., Ltd.

    collaborator INDUSTRY
  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-26
Primary Completion
2024-11-27
Completion
2024-11-27
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04747496 on ClinicalTrials.gov